Vaccine

Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 12/12/2018, Revision: 6, Status: Authorised

Retrieved on: 
Thursday, January 4, 2024
Medical Subject Headings, Marketing, Protein, Fever Dream, INN, Risk, Immune system, Infection, Fever, HIV/AIDS, Woman, Virus, ATC, Antibody, Pain, International, Injection, Headache, Disease, Weakness, Ageing, Language, Vaccination, Red, Allergy, European Medicines Agency, HIV, Vaccine, Myalgia, Select, Dengue virus, Patient, Anatomy, IIA, Skin

Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 12/12/2018, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 12/12/2018, Revision: 6, Status: Authorised

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

Retrieved on: 
Thursday, January 4, 2024
T cell, Immunotherapy, Partnership, Boehringer Ingelheim, Trichloroethylene, Research, TCR, Cancer, Patient, Potyvirus, Vaccine

INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Boehringer Ingelheim and 3T Biosciences ("3T") today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.

Key Points: 
  • INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Boehringer Ingelheim and 3T Biosciences ("3T") today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.
  • Despite the significant transformation of the cancer treatment landscape by immunotherapies, sustained remission only occurs in 15-20% of all cases of cancer.
  • This second research partnership with 3T builds on the successful completion of the initial research partnership announced last year by the two companies.
  • Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.

BIO-TECHNE TO SHOWCASE CELL AND GENE THERAPY MANUFACTURING TOOLS AT PHACILITATE ADVANCED THERAPIES WEEK 2024

Retrieved on: 
Thursday, January 4, 2024
Fresenius (company), EST, Partnership, Workflow, Cell, Hood, RUO, Learning, Education minister, GMP, Miami Beach Convention Center, Vaccine

Bio-Techne's booth (#509) will feature its wide range of products, services, and capabilities that enable cell and gene therapy development and workflow solutions .

Key Points: 
  • Bio-Techne's booth (#509) will feature its wide range of products, services, and capabilities that enable cell and gene therapy development and workflow solutions .
  • David Hermanson, Director for Cell & Gene Therapy Applications at Bio-Techne, will present a technical talk at the conference focusing on how gene modified cell therapies can be manufactured at scale using the TcBuster transposon system, specialty media, and liquid cytokines in the G-Rex® bioreactor.
  • "My presentation will be a wonderful opportunity for attendees to learn how immune cell therapy development programs can benefit from a streamlined T cell manufacturing workflow and licensable transposon system for non-viral gene engineering," said Dr. Hermanson.
  • Friday, January 19th at 10:00AM EST, Theatre 2
    Cell Therapy Manufacturing: A Look Under the Hood - Learning from Outside the Industry.

Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Technology, Other Science, Health, Westin St. Francis, Conference, Atopic dermatitis, Protein, Learning, Cryogenic electron microscopy, Flagship Pioneering, Gateway, AMGN, Generative, Biomedicine, Biomarker, SARS-CoV-2, Safety, Therapy, Vaccine

Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthcare Conference, which will be occurring from January 8-11 in San Francisco.

Key Points: 
  • Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthcare Conference, which will be occurring from January 8-11 in San Francisco.
  • The presentation will take place on January 10 from 10:00-10:25am PST at the Golden Gate (32nd Floor) of The Westin St. Francis.
  • Deploying structure in the learning loop utilizing CryoEM to generate data for iterative learning which has shown faster, improved outcomes.
  • “We look forward to working even more closely together in order to deliver best-in-class therapies that address significant unmet patient needs.”

Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development

Retrieved on: 
Thursday, January 4, 2024
PRAME, TCR, MAGE, Certification, Cancer, GMP, Mutation, CSO, Patient, Vaccine

The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises2 of precision targeted cell therapies for different cancers and covering diverse patient populations.

Key Points: 
  • The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises2 of precision targeted cell therapies for different cancers and covering diverse patient populations.
  • Anocca has built validated asset franchises against valuable cancer targets including KRAS, PRAME and MAGE, with more than 40 preclinical assets in the pipeline.
  • Anocca will initiate its first clinical program in hard-to-treat solid tumour indications with TCR-T therapies across multiple KRAS mutation forms and patient segments.
  • 1 TCR-T therapies: T cell receptor-engineered T cell therapies – a type of cell therapy that uses the natural targeting ability of T cells to identify and eradicate diseased cells like cancer.

Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

Retrieved on: 
Thursday, January 4, 2024
Liver, Conference, NASH, Drug development, Antibody, Cirrhosis, Cancer, Phagocytosis, Federal Medical Centres, DSM-IV codes, Poster, Liver failure, Research fellow, Liver cancer, Diagnosis, Therapy, NK, Vaccine

SHANGHAI and WARREN, N.J., Jan. 3, 2024 /PRNewswire/ -- Laekna (2105.HK), a clinical-stage biotechnology company, today announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah. The presentation will showcase a novel antibody-based aHSC depletion discovery platform and introduce preclinical anti-fibrosis data of a bi-functional NK-aHSC engager candidates derived from this platform.

Key Points: 
  • Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis.
  • This platform enables Laekna to continually discover and develop the next generation therapeutics against liver fibrosis and potentially other types of fibrotic diseases.
  • "Liver fibrosis, metabolic diseases, and cancer are the three major indications that Laekna aims to tackle.
  • In vivo, antibodies with enhanced effector function showed significant anti-fibrotic effects in two different liver fibrosis animal models.

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
PST, EST, Conference, Vaccine, VLP

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST.

Key Points: 
  • BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST.
  • HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Spacecraft, ImmunoGen, Employment, IMGN, RSU, Vaccine

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of December 29, 2023, the grant of restricted stock units (“RSUs”) covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to six new employees.

Key Points: 
  • ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of December 29, 2023, the grant of restricted stock units (“RSUs”) covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to six new employees.
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter for the next three years, subject to the employee’s continued employment on each vesting date.
  • Each RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of an RSU agreement covering the grants.

Novel Genetic Priority Score Unveiled to Enhance Target Prioritization in Drug Development

Retrieved on: 
Wednesday, January 3, 2024
Leducq Foundation, DOI, Drug discovery, Drug development, GPS, MD, Doctor of Philosophy, ANR, Personalized medicine, Nature Genetics, Gene, Lung, NIH, Therapy, Cardiff University, Algorithm, Foundation (nonprofit), Vaccine

NEW YORK, Jan. 3, 2024 /PRNewswire-PRWeb/ -- Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel "genetic priority score" (GPS) that will integrate various types of human genetic data into a single easy-to-interpret score.

Key Points: 
  • The score measures the general ability of a gene to be targeted by drugs; genes with a high score in the new tool are more likely to succeed as a drug target.
  • The score identifies both known drug gene targets as well as potential novel therapeutic targets.
  • The GPS, with its potential to streamline target prioritization, is positioned to have a significant impact on drug development.
  • The paper is titled "Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications."

Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP™

Retrieved on: 
Wednesday, January 3, 2024
Entrepreneurship, CD8, FDA, Group 2, Disease, Trial of the century, Vaccination, Mutation, Water, Volunteering, SARS-CoV-2, Safety, Coronavirus, Group 1, Vaccine

Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point candidate against Betacoronaviruses.

Key Points: 
  • Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point candidate against Betacoronaviruses.
  • Emergex is progressing trial initiation plans, with an anticipated start date in Q2 2024.
  • The naNO-COVID 2 trial (NCT05633446) is a randomized, double-blind, placebo-controlled Phase I-II trial in the Philippines, which will investigate the safety and immunogenicity of CoronaTcP.
  • Professor Thomas Rademacher, Co-Founder and Chief Executive Officer, Emergex, commented: “We thank the Philippines FDA for rapidly approving this trial after a successful Phase I clinical trial in Switzerland.